American Association for Cancer Research (AACR) Annual Meeting 2022
New Orleans 08 April 2022 - 13 April 2022
Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab in combination with platinum-based chemotherapy significantly improves event-free survival (EFS) and shows a trend towards better overall survival (OS) vs chemotherapy alone, without impeding the feasibility of surgery or increasing adverse events (AEs), according to results of the phase III CheckMate 816 trial.
SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.
Sotorasib demonstrates durable efficacy in KRASG12C-mutated NSCLC
The KRASG12C inhibitor sotorasib has demonstrated durable efficacy in patients with locally advanced or metastatic KRASG12C-mutated non-small-cell lung cancer (NSCLC), with 2-year overall survival (OS) reported in one-third of patients in the CodeBreaK 100 trial.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
New chemo-free triplet regimen shows promise for endometrial cancer
A triplet regimen combining the PARP inhibitor olaparib with metronomic cyclophosphamide and metformin showed favourable signals for heavily pretreated women with advanced endometrial carcinoma, the phase I/II ENDOLA study suggests.
